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Background
Advanced therapy medicinal products (ATMPs) are new
medical products based on genes (gene therapy), cells
(cell therapy) and tissues (tissue engineering).
Mycoplasmas are among the world’s smallest bacteria
capable of independent reproduction. They belong to
the class of Mollicutes, have a very slow and parasitic
growth and can cause human infections. Mycoplasma
contaminations of ATMPs can arise from unsterile
source material of different human origin, starting mate-
rials or the complex manufacturing process. The tradi-
tional growth-based detection method requires a
cultivation time of at least 28 days before a contamina-
tion can be ruled out with certainty [1]. But shelf lives
of final ATMPs are often extremely short compared to
classical drugs (24 - 48 h, sometimes only a few hours).
That is why the official culture method or indicator cell
method are not suitable. Furthermore ATMP sample
amounts are usually limited and of great “value”.
Nucleic Acid Amplification Techniques (NAT) allow
reducing time to result to just hours and only small
sample amount are necessary to generate highly sensi-
tive results.
A Mycoplasma Real-time PCR kit was designed espe-
cially for the detection of Mollicutes (Mycoplasma,
Acholeplasma, Spiroplasma) contamination in ATMPs
and cell cultures by using the cells itself, cell culture
supernatant or a defined mixture as test material. An
acceptable sample volume in respect of the expensive,
unique and limited sample is processed for Mycoplasma
detection. In this studies the robustness of the kit was
demonstrated by testing 20 randomly selected Advanced
Therapy Medicinal Products from samples submitted by
customers for Mycoplasma detection. These tests were
done as part of the kit validation. All selected ATMPs
were tested negative for Mycoplasma and could there-
fore be used as spiking matrices for the intended stu-
dies. These 20 different products were spiked with
10 CFU/ml of Mycoplasma fermentans. Each spiked
ATMP matrix was then subjected to a DNA isolation
process and tested by Real-time PCR.
All 20 randomly selected ATMPs out of 20 in total were
tested positive in duplicate and fulfilled the acceptance cri-
terion. These results confirmed the suitability and the
robustness of the designed Mycoplasma Real-time PCR kit
for ATMP testing.
Materials and methods
Two replicates of 20 randomly selected Mycoplasma
negative ATMP samples (see Fig. 1) were spiked with
Mycoplasma fermentans at a final concentration of
10 CFU/ml. 200 µl of each sample were used for silica-
membrane based DNA extraction followed by Real-time
PCR detection on the cycler MxPro 3005P. In parallel
unspiked sample material was processed as a negative
extraction control. After Real-time PCR detection Ct
values were determined and result interpretation was
done.
Results
All 20 randomly selected ATMPs out of 20 in total were
tested positive in duplicate and fulfilled the acceptance
criterion (Ct values < 40). None of the matrices showed
inhibitory effects in the ROX channel (Fig. 1). Mean Ct
values were 32.3 ± 0.9 for FAM and 33.0 ± 0.7 for ROX.
The Real-time PCR used is a multiplex assay which is
able to detect Mollicutes with a FAM-labeled probe and
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an internal control DNA plasmid with a ROX-labeled
probe. The ROX channel is used to check whether the
reaction is inhibited due to matrix effects for example.
A positive signal in the ROX channel indicates the
absence of inhibitory effects and a successful amplifica-
tion reaction.
Conclusions
These studies provided detailed information about the
suitability and robustness of the kit by reflecting influ-
ences of the sample matrices frequently used for manu-
facturing of Advanced Therapy Medicinal Products and
in cell culture technology in general. M. fermentans was
easily detectable at the spiked concentration of 10 CFU/
ml even in highly complex sample matrices.
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Figure 1 Left: Results of 20 ATMP matrices spiked with M. fermentans (10 CFU/ml); FAM channel detects Mycoplasma DNA, ROX channel
visualizes the internal inhibition control reaction; Right: Amplifications curves (FAM channel) of 20 ATMP matrices spiked with M. fermentans (10
CFU/ml)
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